85 results
Page 2 of 5
8-K
EX-1.1
bd4ja hg5
24 Mar 22
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
8:18pm
8-K
EX-1.1
5t0jdi36l36jd
20 Jan 22
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-1.1
pueg kuw2cxi3v
17 Nov 21
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9:04am
8-K
EX-10.1
dg1k 2vdl
8 Jul 21
Entry into a Material Definitive Agreement
7:15am
8-K
EX-10.1
fwnt27za bsa4twkg
7 Jan 21
Entry into a Material Definitive Agreement
7:08am
8-K
EX-99.1
wpuqim5wheql3wqj094
27 Oct 20
Sobi obtains global co-development and exclusive ex-U.S. commercialization rights for systemic pegcetacoplan, a targeted C3 therapy
7:17am
8-K
EX-10.1
hrvrty
7 May 20
Apellis Pharmaceuticals Announces Private Placement of Convertible Senior Notes
7:44am